Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children

Pediatric Infectious Disease Journal

Volumn 21, Issue 3, 2002, Pages 240-248

  Walsh, Thomas J ^a   Lutsar, Irja ^b   Driscoll, Timothy ^c   Dupont, Bertrand ^d   Roden, Maureen ^a   Ghahramani, Parvis ^b   Hodges, Michael ^b   Groll, Andreas H ^a   Perfect, John R ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c DUKE UNIVERSITY   (United States)

^d INSTITUT PASTEUR   (France)

Author keywords

Aspergillosis; Candidiasis; Scedosporiosis; Voriconazole

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; VORICONAZOLE;

ADOLESCENT; ARTICLE; ASPERGILLOSIS; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CANDIDIASIS; CHILD; CHILDHOOD DISEASE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; ENZYME ASSAY; FEMALE; FUSARIUM; GRANULOMATOSIS; HUMAN; INFANT; LEUKEMIA; LIP DISEASE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PHOTOSENSITIVITY; PRIORITY JOURNAL; RASH; SCEDOSPORIOSIS; SCEDOSPORIUM; SPECIES INVASION; TREATMENT FAILURE; TREATMENT OUTCOME; ULCER;

ADOLESCENT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOMATOUS DISEASE, CHRONIC; HEMATOLOGIC NEOPLASMS; HUMANS; INFANT; MALE; MYCOSES; PYRIMIDINES; TREATMENT FAILURE; TRIAZOLES;

EID: 0036191021     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200203000-00015     Document Type: Article

References (38)

1. Invasive fungal infections in children: Recent advances in diagnosis and treatment
2. Five-year survey of invasive aspergillosis in a pediatric cancer centre: Epidemiology, management and long-term survival
3. Aspergillosis in children with cancer: A 34-year experience
4. Invasive aspergillosis in human immunodeficiency virus-infected children
5. Chronic granulomatous disease: Report on a national registry of 368 patients
6. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management
7. Emerging pathogens
8. Emerging fungal pathogens: Evolving challenges to immunocompromised patients for the twenty-first century
9. New approaches to antifungal chemotherapy
10. Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development
11. Current and emerging azole antifungal agents
12. New investigational antifungal agents for treating invasive fungal infections
13. Voriconazole for "salvage" treatment of invasive aspergillosis
14. Voriconazole (VORI) for the treatment of resistant and rare fungal pathogens
15. A rapid HPLC assay for voriconazole in human plasma
16. Invasive aspergillosis during chemotherapy in children
17. Special aspects related to invasive fungal infections in children with cancer
18. Invasive Aspergillus infections in a pediatric hospital: A ten-year review
19. Aspergillosis in children with cancer: A 34-year experience
20. Clinical significance of Pseudallescheria boydii: A review of 10 years' experience
21. Clinical features of human infection with Scedosporium inflatum
22. Disseminated infection by Scedosporium prolificans: An emerging fatality among haematology patients. Case report and review
23. Efficacy of caspofungin as salvage therapy in invasive aspergillosis (IA) as compared to standard therapy in a historical cohort
24. Open, randomized comparison of voriconazole (VRC) and amphotericin B (AmB) followed by other licensed antifungal therapy of invasive aspergillosis (IA)
25. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
26. In vitro activity of voriconazole against selected fungi
27. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi
28. Pharmacokinetics of intravenous voriconazole in children after single and multiple dose administration
29. Aspergillus infections of the central nervous system: A clinicopathological analysis
30. Brain abscess following marrow transplantation: Experience at the Fred Hutchinson Cancer Research Center, 1984-1992
31. Central nervous system infection caused by Pseudallescheria boydii: Case report and review
32. Scedosporium apiospermum pneumonia after autologous bone marrow transplantation
33. Cutaneous infection by Scedosporium apiospermum and its successful treatment with itraconazole
34. Activity of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii
35. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: Case report and literature review of central nervous system pseudallescheriasis
36. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy
37. Deep infections caused by Scedosporium prolificans: A report on 16 cases in Spain and a review of the literature
38. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy in persistently febrile neutropenic patients: A prospective, randomized, multicenter, international trial